Table 2

Safety through 30 days postvaccination with PCV-13

Event, n (%)UPA 15 mg QD
UPA 30 mg QD
Any AE15 (17.2)3 (12.5)
AEs occurring in >1 patient
 Fever2 (2.3)0
 Nasopharyngitis3 (3.4)0
 Onychomycosis2 (2.3)0
 Upper respiratory tract infection1 (1.1)1 (4.2)
Serious AE00
AE leading to discontinuation of study drug00
AE with reasonable possibility of being related to UPA*1 (1.1)1 (4.2)
  • *As assessed by the investigator.

  • AE, adverse event; PCV-13, pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein); QD, once daily; UPA, upadacitinib.